Longevity & AgingNew AMPK Drug Boosts Metabolism and Cuts Liver Fat in Prediabetes Trial
A new drug called ATX-304, developed by Cambrian Bio, showed promising early results in adults with obesity and prediabetes. In an 8-week randomized controlled trial, the drug boosted resting metabolic rate by 8%, significantly lowered triglycerides and liver fat, and reduced visceral belly fat — all without serious side effects. It works by activating the AMPK pathway, a cellular energy sensor linked to improved glucose uptake and mitochondrial function. Adiponectin, a hormone associated with better insulin sensitivity, also increased significantly. The drug appears to improve multiple metabolic markers simultaneously, which is notable for a single compound. Larger Phase 2 trials are planned to test higher doses for muscle function and weight loss.
